Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,447 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ABI-007(Abraxane) Clear all
Completed Phase 2 Interventional Results available

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

NCT00527735
View directory record Official record
Conditions
Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
Ipilimumab, Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 15, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

NCT04132817
View directory record Official record
Conditions
Breast Cancer
Interventions
Nivolumab, Ipilimumab, Nab-paclitaxel
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 15, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

NCT02967133
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
Interventions
Nivolumab, nab-paclitaxel
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Edgewood, Kentucky • Saint Louis Park, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 15, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed

NCT00003235
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
6
States / cities
Elizabeth, New Jersey • Summit, New Jersey • Toms River, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 15, 2026, 5:11 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01386385
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
232
States / cities
Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 5:11 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer

NCT01820325
View directory record Official record
Conditions
Non-Small Cell Lunch Cancer
Interventions
Buparlisib, Buparlisib placebo, Carboplatin, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Fayetteville, Arkansas • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 15, 2026, 5:11 AM EDT
Withdrawn Phase 1Phase 2 Interventional

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03797443
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ascorbic Acid, nab paclitaxel, Cisplatin, Gemcitabine
Drug
Lead sponsor
Piedmont Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Fayetteville, Georgia • Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 15, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional Results available

Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

NCT00454324
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Carboplatin, Abraxane
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 15, 2026, 5:11 AM EDT
Completed Not applicable Interventional

The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions

NCT00217269
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Stenting
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 15, 2026, 5:11 AM EDT
Terminated Not applicable Interventional Results available

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

NCT01369433
View directory record Official record
Conditions
Solid Tumors
Interventions
Tivozanib + paclitaxel, Tivozanib + temsirolimus, Tivozanib, Tivozanib (AV-951), Tivozanib + capecitabine, Tivo
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 15, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

NCT03056833
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
ribociclib, Paclitaxel, Carboplatin
Drug
Lead sponsor
Ronald Buckanovich
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Ann Arbor, Michigan • Bethel Park, Pennsylvania • Greensburg, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 15, 2026, 5:11 AM EDT
Active, not recruiting No phase listed Observational

Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases

NCT07485179
View directory record Official record
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Initiation of pembrolizumab, Initiation of chemotherapy
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 15, 2026, 5:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

NCT04025879
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Tampa, Florida • Atlanta, Georgia • Augusta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 5:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.080: NANT Pancreatic Cancer Vaccine

NCT03586869
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Oxaliplatin, Avelumab, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 15, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00666692
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Bethesda, Maryland • Hershey, Pennsylvania • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 15, 2026, 5:11 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

NCT02962063
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
durvalumab, carboplatin AUC 2/paclitaxel, External beam radiation (EBRT), esophagogastrectomy, Tremelimumab
Biological · Drug · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 5:11 AM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03587311
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anetumab Ravtansine, Bevacizumab, Paclitaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
22
States / cities
Orange, California • Aurora, Colorado • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 5:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

NCT02075021
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Lenalidomide, nab-paclitaxel
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 15, 2026, 5:11 AM EDT
Recruiting Phase 3 Interventional

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions
daraxonrasib, gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 15, 2026, 5:11 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 15, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00040794
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, gefitinib, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 15, 2026, 5:11 AM EDT
Terminated Phase 1 Interventional

The Seven Trial: Exploiting the Unfolded Protein Response

NCT06076837
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions
Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 15, 2026, 5:11 AM EDT
Suspended Phase 2 Interventional

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00278122
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
sargramostim, paclitaxel
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 15, 2026, 5:11 AM EDT
Suspended Phase 3 Interventional Results available

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

NCT02037529
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
39
States / cities
Scottsdale, Arizona • Newark, Delaware • Washington D.C., District of Columbia + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 15, 2026, 5:11 AM EDT